```
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *
FILE 'HOME' ENTERED AT 13:33:49 ON 28 SEP 2004
=> FILE BIOSIS, CABA, CAPLUS, EMBASE, JAPIO, LIFESCI, MEDLINE, SCISEARCH, USPATFULL
=> e zlotnick gary w/au
E1           91     ZLOTNICK G W/AU
E2            5     ZLOTNICK GARY/AU
E3           42 --> ZLOTNICK GARY W/AU
E4            1     ZLOTNICK GARY WARREN/AU
E5            2     ZLOTNICK GREGORY/AU
E6            6     ZLOTNICK H/AU
E7            2     ZLOTNICK HERBERT/AU
E8            1     ZLOTNICK I/AU
E9           13     ZLOTNICK J/AU
E10          10     ZLOTNICK J A/AU
E11           2     ZLOTNICK JACK/AU
E12           1     ZLOTNICK JAN/AU

=> s e1-e4
L1          139 ("ZLOTNICK G W"/AU OR "ZLOTNICK GARY"/AU OR "ZLOTNICK GARY W"/AU
                OR "ZLOTNICK GARY WARREN"/AU)

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2           66 DUP REM L1 (73 DUPLICATES REMOVED)

=> s l2 and los?
L3           11 L2 AND LOS?

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 11 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 11  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   2002:278490  BIOSIS
DN   PREV200200278490
TI   Preparation and uses of   ***LOS***  -depleted outer membrane proteins of
     gram-negative cocci.
AU     ***Zlotnick, Gary W.***   [Inventor, Reprint author]
CS   Penfield, NY, USA
     ASSIGNEE: American Cyanamid Company
PI   US 6355253 March 12, 2002
SO   Official Gazette of the United States Patent and Trademark Office Patents,
     (Mar. 12, 2002) Vol. 1256, No. 2. http://www.uspto.gov/web/menu/patdata.ht
     ml. e-file.
     CODEN: OGUPE7. ISSN: 0098-1133.
DT   Patent
LA   English
ED   Entered STN: 8 May 2002
     Last Updated on STN: 8 May 2002
AB   Described herein is a method for removing toxic lipooligosaccharide (
       ***LOS***  ) from outer membranes of Gram-negative cocci, such as
     Neisseria meningitidis.    ***LOS***  -depleted outer membranes and
       ***LOS***  -depleted soluble outer membrane proteins can be prepared,
     which are able to elicit bactericidal antibodies against homologous
     strains of bacteria.  Vaccines and other uses of the preparations are
     further described.

L3   ANSWER 2 OF 11  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   1988:256668  BIOSIS
DN   PREV198834127698; BR34:127698
TI     ***LOSS***   OF ANTIGENICITY AND IMMUNOGENICITY BY A PEPTIDOGLYCAN
     ASSOCIATED LIPOPROTEIN OF HAEMOPHILUS-INFLUENZAE FOLLOWING REMOVAL OF
     ESTER LINKED FATTY ACYL GROUPS.
AU     ***ZLOTNICK G W***   [Reprint author]; SANFILIPPO V T; KIRKLEY D H;
     WILHELM S
CS   PRAXIS BIOL, INC, ROCHESTER, NY 14623, USA
SO   FASEB Journal, (1988) Vol. 2, No. 4, pp. ABSTRACT 3445.
     Meeting Info.: 72ND ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES
     FOR EXPERIMENTAL BIOLOGY, LAS VEGAS, NEVADA, USA, MAY 1-5, 1988. FASEB
     (FED AM SOC EXP BIOL) J.
```

CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 21 May 1988
Last Updated on STN: 21 May 1988

L3 ANSWER 3 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1977:38588 BIOSIS
DN PREV197713038588; BR13:38588
TI RETENTION OF BOUND NUCLEOTIDES AND ***LOSS*** OF ENZYME ACTIVITY AFTER CHYMOTRYPSIN MODIFICATION OF BACTERIAL ATPASE.
AU ***ZLOTNICK G W***
SO Federation Proceedings, (1977) Vol. 36, No. 3, pp. 901.
CODEN: FEPRA7. ISSN: 0014-9446.
DT Article
FS BR
LA Unavailable

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:260096 CAPLUS
DN 122:38807
TI lipooligosaccharide-depleted antigenic outer membrane proteins of gram-negative cocci
IN ***Zlotnick, Gary W.***
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 624376	A1	19941117	EP 1994-106827	19940502
	EP 624376	B1	20000315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 190502	E	20000415	AT 1994-106827	19940502
	ES 2145072	T3	20000701	ES 1994-106827	19940502
	PT 624376	T	20000731	PT 1994-106827	19940502
	CA 2123355	AA	19941114	CA 1994-2123355	19940511
	JP 08019396	A2	19960123	JP 1994-122032	19940512
	GR 3033469	T3	20000929	GR 2000-401165	20000522
PRAI	US 1993-61581	A	19930513		

AB A method for removing toxic lipooligosaccharide (***LOS***) from outer membranes of gram-neg. cocci, such as Neisseria meningitidis, is presented. Total membranes of the coccus are extd. with PEG to produce outer membranes depleted of inner membranes; the outer membranes are then extd. with a zwitterionic betaine detergent to remove ***LOS*** . The ***LOS*** -depleted outer membranes are able to elicit bactericidal antibodies against homologous strains of bacteria, and are useful in vaccines.

L3 ANSWER 5 OF 11 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 88:165601 SCISEARCH
GA The Genuine Article (R) Number: M6121
TI ***LOSS*** OF ANTIGENICITY AND IMMUNOGENICITY BY A PEPTIDOGLYCAN ASSOCIATED LIPOPROTEIN OF HEMOPHILUS-INFLUENZAE FOLLOWING REMOVAL OF ESTER LINKED FATTY ACYL-GROUPS
AU ***ZLOTNICK G W (Reprint)*** ; SANFILIPPO V T; KIRKLEY D H; WILHELM S
CS PRAXIS BIOL INC, ROCHESTER, NY, 14623
CYA USA
SO FASEB JOURNAL, (1988) Vol. 2, No. 4, pp. A888.
DT Conference; Journal
FS LIFE
LA ENGLISH
REC No References

L3 ANSWER 6 OF 11 USPATFULL on STN
AN 2004:215959 USPATFULL

TI Novel immunogenic compositions for the prevention and treatment of meningococcal disease
IN ***Zlotnick, Gary W.*** , New Windsor, NY, UNITED STATES
Fletcher, Leah Diane, Geneseo, NY, UNITED STATES
Farley, John Erwin, Rochester, NY, UNITED STATES
Bernfield, Liesel A., Pittsford, NY, UNITED STATES
Zagursky, Robert J., Victor, NY, UNITED STATES
Metcalf, Benjamin J., Rochester, NY, UNITED STATES
PI US 2004167068 A1 20040826
AI US 2003-652870 A1 20030902 (10)
PRAI US 2002-406934P 20020830 (60)
DT Utility
FS APPLICATION
LREP HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109
CLMN Number of Claims: 107
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 11599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

L3 ANSWER 7 OF 11 USPATFULL on STN
AN 2002:250803 USPATFULL
TI Preparation and uses of ***los*** -depleted outer membrane proteins of gram-negative cocci
IN ***Zlotnick, Gary W.*** , Penfield, NY, UNITED STATES
PA American Cyanamid Company, Madison, NY, UNITED STATES (U.S. corporation)
PI US 2002136741 A1 20020926
AI US 2002-91233 A1 20020305 (10)
RLI Division of Ser. No. US 1995-469842, filed on 6 Jun 1995, GRANTED, Pat. No. US 6355253 Continuation-in-part of Ser. No. US 1993-61581, filed on 13 May 1993, ABANDONED
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein is a method for removing toxic lipooligosaccharide (***LOS***) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. ***LOS*** -depleted outer membranes and ***LOS*** -depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.

L3 ANSWER 8 OF 11 USPATFULL on STN
AN 93:22623 USPATFULL
TI Recombinant vectors for Haemophilus influenzae peptides and proteins
IN Anilionis, Algis, Pittsford, NY, United States
Seid, Jr., Robert C., San Francisco, CA, United States
Deich, Robert A., Rochester, NY, United States
Zlotnick, Gary W. , Penfield, NY, United States
Green, Bruce A., Pittsford, NY, United States
PA Praxis Biologics, Inc., Rochester, NY, United States (U.S. corporation)
PI US 5196338 19930323
AI US 1990-480396 19900215 (7)
RLI Division of Ser. No. US 1989-396572, filed on 21 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-239572, filed on 1 Sep 1988, now patented, Pat. No. US 5098997 which is a

continuation-in-part of Ser. No. US 1987-132073, filed on 11 Dec 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-20849, filed on 2 Mar 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-948364, filed on 31 Dec 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lacey, David L.; Assistant Examiner: Ulm, John D.
LREP Gordon, Alan M., Baldwin, Geraldine F.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 3534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides, proteins and fusion proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides, proteins and fusion proteins in hybridization assays is also described.

L3 ANSWER 9 OF 11 USPATFULL on STN
AN 92:36293 USPATFULL
TI Haemophilus influenzae peptides and proteins
IN Deich, Robert A., Rochester, NY, United States
Zlotnick, Gary , Penfield, NY, United States
Green, Bruce, Pittsford, NY, United States
PA Praxis Biologics, Inc., Rochester, NY, United States (U.S. corporation)
PI US 5110908 19920505
AI US 1989-436092 19891109 (7)
RLI Continuation of Ser. No. US 1987-20849, filed on 2 Mar 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-948364, filed on 31 Dec 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Gordon, Alan M., Baldwin, Geraldine F.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1,2
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 2140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.

L3 ANSWER 10 OF 11 USPATFULL on STN
AN 92:33906 USPATFULL

TI Vaccines for Haemophilus influenzae
IN Deich, Robert A., Rochester, NY, United States
Zlotnick, Gary W. , Penfield, NY, United States
Green, Bruce A., Pittsford, NY, United States
PA Praxis Biologics, Inc., Rochester, NY, United States (U.S. corporation)
PI US 5108744 19920428
AI US 1989-434625 19891109 (7)
RLI Continuation of Ser. No. US 1986-948364, filed on 31 Dec 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Gordon, Alan M., Baldwin, Geraldine F.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1,2
DRWN 15 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 2083
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods includng novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequence encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.

L3 ANSWER 11 OF 11 USPATFULL on STN
AN 92:23281 USPATFULL
TI Vaccines for Haemophilus influenzae
IN Anilionis, Algis, Pittsford, NY, United States
Seid, Jr., Robert C., Pittsford, NY, United States
Deich, Robert A., Rochester, NY, United States
Zlotnick, Gary W. , Penfield, NY, United States
Green, Bruce A., Pittsford, NY, United States
PA Praxis Biologics, Inc., Rochester, NY, United States (U.S. corporation)
PI US 5098997 19920324
AI US 1988-239572 19880901 (7)
RLI Continuation-in-part of Ser. No. US 1987-132073, filed on 11 Dec 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-20849, filed on 2 Mar 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-948364, filed on 31 Dec 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Hoffer, Florina B.
LREP Pennie & Edmonds
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 3191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and

viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides, proteins and fusion proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides, proteins and fusion proteins in hybridization assays is also described.

```
=> s lipooligosaccharide?
L4        4041 LIPOOLIGOSACCHARIDE?

=> s l4 and (gram negative cocc?)
L5           9 L4 AND (GRAM NEGATIVE COCC?)

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6            7 DUP REM L5 (2 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y


L6   ANSWER 1 OF 7  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on STN
     DUPLICATE 1
AN   2002:278490  BIOSIS
DN   PREV200200278490
TI   Preparation and uses of LOS-depleted outer membrane proteins of
       ***gram***  -  ***negative***     ***cocci***  .
AU   Zlotnick, Gary W. [Inventor, Reprint author]
CS   Penfield, NY, USA
     ASSIGNEE: American Cyanamid Company
PI   US 6355253 March 12, 2002
SO   Official Gazette of the United States Patent and Trademark Office Patents,
     (Mar. 12, 2002) Vol. 1256, No. 2. http://www.uspto.gov/web/menu/patdata.ht
     ml. e-file.
     CODEN: OGUPE7. ISSN: 0098-1133.
DT   Patent
LA   English
ED   Entered STN: 8 May 2002
     Last Updated on STN: 8 May 2002
AB   Described herein is a method for removing toxic
       ***lipooligosaccharide***   (LOS) from outer membranes of   ***Gram***  -
       ***negative***     ***cocci***  , such as Neisseria meningitidis.
     LOS-depleted outer membranes and LOS-depleted soluble outer membrane
     proteins can be prepared, which are able to elicit bactericidal antibodies
     against homologous strains of bacteria.  Vaccines and other uses of the
     preparations are further described.

L6   ANSWER 2 OF 7  USPATFULL on STN
AN     2002:250803  USPATFULL
TI     Preparation and uses of los-depleted outer membrane proteins of
         ***gram***  -  ***negative***     ***cocci***
IN     Zlotnick, Gary W., Penfield, NY, UNITED STATES
PA     American Cyanamid Company, Madison, NY, UNITED STATES (U.S. corporation)
PI     US 2002136741      A1   20020926
AI     US 2002-91233      A1   20020305 (10)
RLI    Division of Ser. No. US 1995-469842, filed on 6 Jun 1995, GRANTED, Pat.
       No. US 6355253 Continuation-in-part of Ser. No. US 1993-61581, filed on
       13 May 1993, ABANDONED
DT     Utility
FS     APPLICATION
LREP   HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
       9133, CONCORD, MA, 01742-9133
CLMN   Number of Claims: 29
ECL    Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Described herein is a method for removing toxic
         ***lipooligosaccharide***   (LOS) from outer membranes of   ***Gram***
       -  ***negative***     ***cocci***  , such as Neisseria
```

meningitidis.LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.

L6 ANSWER 3 OF 7 USPATFULL on STN
AN 2002:192044 USPATFULL
TI Therapeutic uses of BPI protein products for human meningococcemia
IN Giroir, Brett P., Dallas, TX, UNITED STATES
Scannon, Patrick J., San Francisco, CA, UNITED STATES
PA XOMA Corporation and The Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002103114 A1 20020801
US 6596691 B2 20030722
AI US 2000-728938 A1 20001130 (9)
RLI Continuation of Ser. No. US 1999-365858, filed on 3 Aug 1999, PATENTED
Continuation of Ser. No. US 1998-203159, filed on 1 Dec 1998, PATENTED
Continuation of Ser. No. US 1997-927437, filed on 10 Sep 1997, PATENTED
Continuation of Ser. No. US 1996-644287, filed on 10 May 1996, ABANDONED
DT Utility
FS APPLICATION
LREP MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER DRIVE, CHICAGO, IL, 60606-6402
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

L6 ANSWER 4 OF 7 USPATFULL on STN
AN 2001:82743 USPATFULL
TI Therapeutic uses of BPI protein products for human meningococcemia
IN Giroir, Brett P., Dallas, TX, United States
Scannon, Patrick J., San Francisco, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
The Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6242418 B1 20010605
AI US 1999-365858 19990803 (9)
RLI Continuation of Ser. No. US 1998-203159, filed on 1 Dec 1998, now patented, Pat. No. US 5990086 Continuation of Ser. No. US 1997-927437, filed on 10 Sep 1997, now patented, Pat. No. US 5888977 Continuation of Ser. No. US 1996-644287, filed on 10 May 1996, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed, Abdel A.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

L6 ANSWER 5 OF 7 USPATFULL on STN
AN 1999:151189 USPATFULL
TI Therapeutic uses of BPI protein products for human meningococcemia
IN Giroir, Brett P., Dallas, TX, United States
Scannon, Patrick J., San Francisco, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5990086 19991123
AI US 1998-203159 19981201 (9)
RLI Continuation of Ser. No. US 1997-927437, filed on 10 Sep 1997, now patented, Pat. No. US 5888977 which is a continuation of Ser. No. US 1996-644287, filed on 10 May 1996, now abandoned which is a

continuation-in-part of Ser. No. US 1995-378228, filed on 24 Jan 1995, now patented, Pat. No. US 5753620 which is a continuation-in-part of Ser. No. US 1994-291112, filed on 16 Aug 1994, now patented, Pat. No. US 5643875 which is a continuation-in-part of Ser. No. US 1994-188221, filed on 24 Jan 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Mohamed, Abdel A.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

L6 ANSWER 6 OF 7 USPATFULL on STN
AN 1999:40396 USPATFULL
TI Therapeutic uses of BPI protein products for human meningococcemia
IN Giroir, Brett P., 6231 Pemberton Dr., Dallas, TX, United States 75230
Scannon, Patrick J., 176 Edgewood Ave., San Francisco, CA, United States 94117
PI US 5888977 19990330
AI US 1997-927437 19970910 (8)
RLI Continuation of Ser. No. US 1996-644287, filed on 10 May 1996, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Mohamed, Abdel A.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:260096 CAPLUS
DN 122:38807
TI ***lipooligosaccharide*** -depleted antigenic outer membrane proteins of ***gram*** - ***negative*** ***cocci***
IN Zlotnick, Gary W.
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 624376	A1	19941117	EP 1994-106827	19940502
EP 624376	B1	20000315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 190502	E	20000415	AT 1994-106827	19940502
ES 2145072	T3	20000701	ES 1994-106827	19940502
PT 624376	T	20000731	PT 1994-106827	19940502
CA 2123355	AA	19941114	CA 1994-2123355	19940511
JP 08019396	A2	19960123	JP 1994-122032	19940512
GR 3033469	T3	20000929	GR 2000-401165	20000522
PRAI US 1993-61581	A	19930513		

AB A method for removing toxic ***lipooligosaccharide*** (LOS) from outer membranes of gram-neg. cocci, such as Neisseria meningitidis, is presented. Total membranes of the coccus are extd. with PEG to produce outer membranes depleted of inner membranes; the outer membranes are then

extd. with a zwitterionic betaine detergent to remove LOS. The LOS-depleted outer membranes are able to elicit bactericidal antibodies against homologous strains of bacteria, and are useful in vaccines.

```
=> s l4 and polyoxyethylene
L7          25 L4 AND POLYOXYETHYLENE

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8           24 DUP REM L7 (1 DUPLICATE REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y


L8   ANSWER 1 OF 24  USPATFULL on STN
AN     2004:189756  USPATFULL
TI     Stabilized immunogenic HBc chimer particles
IN     Lyons, Katelynne, Carlsbad, CA, UNITED STATES
       Birkett, Ashley J., Escondido, CA, UNITED STATES
       Haron, Jay A., Jamul, CA, UNITED STATES
PI     US 2004146524      A1   20040729
AI     US 2003-732862     A1   20031210 (10)
RLI    Continuation-in-part of Ser. No. US 2002-274616, filed on 21 Oct 2002,
       PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb
       2002, PENDING Continuation-in-part of Ser. No. US 2002-82014, filed on
       21 Feb 2002, PENDING
PRAI   US 2002-432123P     20021210 (60)
DT     Utility
FS     APPLICATION
LREP   WELSH & KATZ, LTD, 120 S RIVERSIDE PLAZA, 22ND FLOOR, CHICAGO, IL, 60606
CLMN   Number of Claims: 46
ECL    Exemplary Claim: 1
DRWN   11 Drawing Page(s)
LN.CNT 8390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid
       (core) protein (HBc) that is engineered for both enhanced stability of
       self-assembled particles and the substantial absence of nucleic acid
       binding by those particles is disclosed. The chimeric protein molecule
       can include one or more immunogenic epitopes peptide-bonded to one or
       more of the N-terminus, the immunogenic loop or the C-terminus of HBc.
       The enhanced stability of self-assembled particles is obtained by the
       presence of at least one heterologous cysteine residue near one or both
       of the amino-terminus and carboxy-terminus of the chimer molecule and
       the absence of the cysteine residues present in the native sequence at
       HBc positions 48 and 107.

L8   ANSWER 2 OF 24  USPATFULL on STN
AN     2004:184970  USPATFULL
TI     Glycoconjugation methods and proteins/peptides produced by the methods
IN     DeFrees, Shawn, North Wales, PA, UNITED STATES
       Zopf, David, Wayne, PA, UNITED STATES
       Bayer, Robert, San Diego, CA, UNITED STATES
       Bowe, Caryn, Doylestown, PA, UNITED STATES
       Hakes, David, Willow Grove, PA, UNITED STATES
       Chen, Xi, Lansdale, PA, UNITED STATES
PA     Neose Technologies, Inc. (U.S. corporation)
PI     US 2004142856      A1   20040722
AI     US 2003-410913     A1   20030409 (10)
RLI    Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003,
       PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan
       2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on
       5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9
       Oct 2002, PENDING
PRAI   US 2002-407527P     20020828 (60)
       US 2002-407527P     20020828 (60)
       US 2002-404249P     20020816 (60)
       US 2002-396594P     20020717 (60)
       US 2002-391777P     20020625 (60)
```

US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
US 2001-334692P 20011121 (60)
US 2001-328523P 20011010 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 16544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 3 OF 24 USPATFULL on STN
AN 2004:178391 USPATFULL
TI Remodeling and glycoconjugation of peptides
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004137557 A1 20040715
AI US 2002-287994 A1 20021105 (10)
RLI Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 447
ECL Exemplary Claim: 1
DRWN 345 Drawing Page(s)
LN.CNT 16205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.

L8 ANSWER 4 OF 24 USPATFULL on STN
AN 2004:172476 USPATFULL
TI Glycopegylation methods and proteins/peptides produced by the methods
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004132640 A1 20040708
AI US 2003-411012 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)

DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 19255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 5 OF 24 USPATFULL on STN
AN 2004:165351 USPATFULL
TI Follicle stimulating hormone: remodeling and glycoconjugation of FSH
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004126838 A1 20040701
AI US 2003-410997 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 115
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 19355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 6 OF 24 USPATFULL on STN
AN 2004:164895 USPATFULL
TI Intranasal immunization with detoxified ***lipooligosaccharide*** from nontypeable haemophilus influenzae or moraxella
IN Gu, Xin-Xing, Potomac, MD, UNITED STATES
PI US 2004126381 A1 20040701
AI US 2003-688115 A1 20031017 (10)
RLI Continuation of Ser. No. WO 2001-US32331, filed on 16 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-789017, filed on 20 Feb 2001, GRANTED, Pat. No. US 6607725 Division of Ser. No. US 1997-842409, filed on 23 Apr 1997, GRANTED, Pat. No. US 6207157 Continuation-in-part of Ser. No. US 2000-610034, filed on 5 Jul 2000, GRANTED, Pat. No. US 6685949 Continuation of Ser. No. WO 1999-US590, filed on 12 Jan 1999, PENDING
PRAI US 2001-288695P 20010503 (60)
US 1996-16020P 19960423 (60)
US 1998-71483P 19980113 (60)
DT Utility
FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 1405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to intranasal immunization with detoxified ***lipooligosaccharide*** from nontypeable Haemophilus influenzae or Moraxella catarrhalis.

L8 ANSWER 7 OF 24 USPATFULL on STN
AN 2004:150947 USPATFULL
TI Interferon beta: remodeling and glycoconjugation of interferon beta
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004115168 A1 20040617
AI US 2003-410930 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
US 2001-344692P 20011019 (60)
US 2001-328523P 20011010 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 119
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 19412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 8 OF 24 USPATFULL on STN
AN 2004:107626 USPATFULL
TI Interferon alpha: remodeling and glycoconjugation of interferon alpha
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004082026 A1 20040429
AI US 2003-411049 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)

US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
US 2001-344692P 20011019 (60)
US 2001-328523P 20011010 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 126
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 19445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes a multitude of methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 9 OF 24 USPATFULL on STN
AN 2004:101966 USPATFULL
TI Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004077836 A1 20040422
AI US 2003-410962 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
US 2001-344692P 20011019 (60)
US 2001-328523P 20011010 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 111
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 19316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 10 OF 24 USPATFULL on STN
AN 2004:83455 USPATFULL
TI Protein remodeling methods and proteins/peptides produced by the methods
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004063911 A1 20040401

AI US 2003-411026 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
US 2001-344692P 20011019 (60)
US 2001-328523P 20011010 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 18872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 11 OF 24 USPATFULL on STN
AN 2004:57444 USPATFULL
TI Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A
IN DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PA Neose Technologies, Inc. (U.S. corporation)
PI US 2004043446 A1 20040304
AI US 2003-411037 A1 20030409 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING
PRAI US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 122
ECL Exemplary Claim: 1
DRWN 497 Drawing Page(s)
LN.CNT 19395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L8 ANSWER 12 OF 24 USPATFULL on STN
AN 2003:282324 USPATFULL
TI Enhanced circulation effector composition and method
IN Zalipsky, Samuel, Redwood City, CA, UNITED STATES
Woodle, Martin C., Menlo Park, CA, UNITED STATES
Martin, Francis J., San Francisco, CA, UNITED STATES
Barenholz, Yechezkel, Jerusalem, ISRAEL
Bercovier, Herve, Jerusalem, ISRAEL

PA Alza Corporation (U.S. corporation)
PI US 2003198665 A1 20031023
AI US 2003-438502 A1 20030514 (10)
RLI Continuation of Ser. No. US 2001-877978, filed on 8 Jun 2001, GRANTED, Pat. No. US 6586002 Continuation of Ser. No. US 1995-480332, filed on 7 Jun 1995, GRANTED, Pat. No. US 6180134 Continuation-in-part of Ser. No. US 1994-316436, filed on 29 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-35443, filed on 23 Mar 1993, GRANTED, Pat. No. US 6326353
DT Utility
FS APPLICATION
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 1662
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

L8 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 2002:180973 CAPLUS
DN 136:231229
TI Preparation and immunogenicity of ***lipooligosaccharide*** -depleted outer membrane proteins of Gram-negative cocci
IN Zlotnick, Gary W.
PA American Cyanamid Company, USA
SO U.S., 13 pp., Cont.-in-part of U.S. Ser. No. 61,581, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355253	B1	20020312	US 1995-469842	19950606
	AT 190502	E	20000415	AT 1994-106827	19940502
	ES 2145072	T3	20000701	ES 1994-106827	19940502
	PT 624376	T	20000731	PT 1994-106827	19940502
	CA 2123355	AA	19941114	CA 1994-2123355	19940511
	JP 08019396	A2	19960123	JP 1994-122032	19940512
	GR 3033469	T3	20000929	GR 2000-401165	20000522
	US 2002136741	A1	20020926	US 2002-91233	20020305
PRAI	US 1993-61581	B2	19930513		
	US 1995-469842	A3	19950606		

AB The author discloses a method for removing ***lipooligosaccharide*** (LOS) from outer membranes of Gram-neg. cocci, such as Neisseria meningitidis. The method is comprised of sequential extn. of bacterial membranes with (1) a ***polyoxyethylene*** detergent (e.g., Triton X-100) followed by (2) a zwitterionic betaine detergent. LOS-depleted outer membranes and LOS-depleted sol. outer membrane proteins of N. meningitidis are able to elicit bactericidal antibodies against homologous strains of the bacteria.
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 24 USPATFULL on STN
AN 2002:250803 USPATFULL
TI Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
IN Zlotnick, Gary W., Penfield, NY, UNITED STATES
PA American Cyanamid Company, Madison, NY, UNITED STATES (U.S. corporation)
PI US 2002136741 A1 20020926
AI US 2002-91233 A1 20020305 (10)
RLI Division of Ser. No. US 1995-469842, filed on 6 Jun 1995, GRANTED, Pat. No. US 6355253 Continuation-in-part of Ser. No. US 1993-61581, filed on 13 May 1993, ABANDONED
DT Utility

FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein is a method for removing toxic ***lipooligosaccharide*** (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis.LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.

L8 ANSWER 15 OF 24 USPATFULL on STN
AN 2002:205882 USPATFULL
TI Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
IN Granoff, Dan M., Berkeley, CA, UNITED STATES
Moe, Gregory R., Alameda, CA, UNITED STATES
PI US 2002110569 A1 20020815
AI US 2001-917222 A1 20010727 (9)
PRAI US 2000-221495P 20000727 (60)
DT Utility
FS APPLICATION
LREP Carol L. Francis, Bozicevic, Field and Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 2727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally provides methods and vaccines for the prevention of diseases caused by Neisseria meningitidis bacteria, particularly serogroup B strains.

L8 ANSWER 16 OF 24 USPATFULL on STN
AN 2002:84912 USPATFULL
TI Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
IN Liu, Gui, Medford, MA, UNITED STATES
Beltz, Gerald, Lexington, MA, UNITED STATES
LeClair, Kenneth, Needham, MA, UNITED STATES
Cox, Daniel, Medway, MA, UNITED STATES
Kensil, Charlotte, Milford, MA, UNITED STATES
PI US 2002044951 A1 20020418
AI US 2001-825789 A1 20010404 (9)
PRAI US 2000-194519P 20000404 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 1185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nonpeptide antigens were isolated and purified from Mycobacterium tuberculosis. The antigens were used in vaccine compositions, pharmaceutical compositions and methods to elicit an immune response to Mycobacterium tuberculosis in a mammal.

L8 ANSWER 17 OF 24 USPATFULL on STN
AN 2001:211937 USPATFULL
TI Enhanced circulation effector composition and method
IN Zalipsky, Samuel, Redwood City, CA, United States
Woodle, Martin C., Menlo Park, CA, United States
Martin, Francis J., San Francisco, CA, United States
Barenholz, Yechezkel, Jerusalem, Israel
Bercovier, Herve, Jerusalem, Israel

PA Alza Corporation (U.S. corporation)
PI US 2001043929 A1 20011122
US 6586002 B2 20030701
AI US 2001-877978 A1 20010608 (9)
RLI Continuation of Ser. No. US 1995-480332, filed on 7 Jun 1995, GRANTED, Pat. No. US 6180134 Continuation-in-part of Ser. No. US 1994-316436, filed on 29 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-35443, filed on 23 Mar 1993, PENDING
DT Utility
FS APPLICATION
LREP IOTA PI LAW GROUP, 350 CAMBRIDGE AVENUE SUITE 250, P O BOX 60850, PALO ALTO, CA, 94306-0850
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 1477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

L8 ANSWER 18 OF 24 USPATFULL on STN
AN 2001:221031 USPATFULL
TI Enhanced circulation effector composition and method
IN Zalipsky, Samuel, Fremont, CA, United States
Woodle, Martin C., Menlo Park, CA, United States
Martin, Francis J., San Francisco, CA, United States
Barenholz, Yechezkel, Jerusalem, Israel
PA Sequus Pharmaceuticals, Inc., Menlo Park, CA, United States (U.S. corporation)
PI US 6326353 B1 20011204
AI US 1993-35443 19930323 (8)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saunders, David
LREP Dehlinger, Peter J., Mohr, Judy M., Simboli, Paul B.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

L8 ANSWER 19 OF 24 USPATFULL on STN
AN 2001:13992 USPATFULL
TI Enhanced ciruclation effector composition and method
IN Zalipsky, Samuel, Redwood City, CA, United States
Woodle, Martin C., Menlo Park, CA, United States
Martin, Francis J., San Francisco, CA, United States
Barenholz, Yechezkel, Jersusalem, Israel
PA Sequus Pharmaceuticals, Inc., Menlo Park, CA, United States (U.S. corporation)
PI US 6180134 B1 20010130
AI US 1995-480332 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-316436, filed on 29 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 1993-35443, filed on 23 Mar 1993
DT Utility
FS Granted
EXNAM Primary Examiner: Huff, Sheela
LREP Mohr, Judy M.Iota Pi Law Group
CLMN Number of Claims: 7
ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 1565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

L8 ANSWER 20 OF 24 USPATFULL on STN
AN 1998:82718 USPATFULL
TI Anti-LPS factor from horseshoe crabs and methods of use
IN Wainwright, Norman R., Falmouth, MA, United States
PA Marine Biological Laboratory, Woods Hole, MA, United States (U.S. corporation)
PI US 5780429 19980714
AI US 1995-577464 19951222 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Hale and Dorr LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 4
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 843
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to pharmaceutical and cosmetic compositions comprising anti-lipopolysaccharide (anti-LPS) factor proteins derived from horseshoe crabs, either in the native form or produced by recombinant means. The pharmaceutical formulations, which may include anti-LPS factor proteins alone or in combination with other antimicrobials, may be used in the treatment of gram-negative bacterial infections, endotoxemia, septic shock, gram-positive bacterial infections, and yeast infections. The anti-LPS factor protein-containing pharmaceuticals can be formulated for systemic or topical administration. They may also be used to control mold growth. Anti-LPS factor proteins can be used in cosmetic compositions or skin or hair preparations as antimicrobial preservatives, either alone or in combination with conventional preservatives, to prevent or control the growth of bacteria, yeast and mold.

L8 ANSWER 21 OF 24 USPATFULL on STN
AN 1998:1454 USPATFULL
TI Immunogenic meningococcal LPS and other membrane vesicles and vaccine therefrom
IN Van Der Ley, Peter Andre, Utrecht, Netherlands
Poolman, Jan Theunis, Broek in Waterland, Netherlands
Hoogerhout, Peter, Bilthoven, Netherlands
PA De Staat der Nederlanden, Vertegenwoordigd Door de Minister Van Welzijn, Volksgezondheid en Cultuur, Rijswijk, Netherlands (non-U.S. corporation)
PI US 5705161 19980106
WO 9408021 19940414
AI US 1995-411727 19950501 (8)
WO 1993-NL163 19930730
19950501 PCT 371 date
19950501 PCT 102(e) date
PRAI NL 1992-1716 19921002
DT Utility
FS Granted
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer
LREP Young & Thompson
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1934
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to an immunity providing B cell activating molecule derived from a meningococcal lipopolysaccharide (LPS) having at least one epitope, said molecule comprising at least the communal part

of the oligosaccharide part (core region) of lipopolysaccharides specific for at least two meningococcal immunotypes, preferably immunotypes L2 and L3 and wherein in galactose is absent in the B cell activating part, as well as derivatives of the molecules with immuno reaction inducing capacity. The invention is also directed at an outer membrane vesicle provided with a group of polypeptides having at least the immunoactivity of outer membrane proteins (OMP's) bound to a membrane, a polypeptide from the group of said outer membrane vesicles being a membrane anchored OMP or OMP fragment with a mutation in one of the surface loops, preferably in a 2, 3, 5, 6, 7 or 8-loop of a class I OMP. Furthermore, the invention is directed at a vaccine comprising such an outer membrane vesicle and/or lipopolysaccharide, as well as methods for preparing a lipopolysaccharide and an outer membrane vesicle as described above.

L8 ANSWER 22 OF 24 USPATFULL on STN
AN 94:90936 USPATFULL
TI Method for detection of gram-negative bacterial liposaccharides in biological fluids
IN Hansen, Eric J., Plano, TX, United States
Munford, Robert S., Dallas, TX, United States
Mertsola, Jussi, Kaarina, Finland
PA Board of Regents, The University of Texas, Austin, TX, United States (U.S. corporation)
PI US 5356778 19941018
WO 9201228 19920123
AI US 1993-972498 19930205 (7)
WO 1991-US4864 19910710
19930205 PCT 371 date
19930205 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1990-553072, filed on 13 Jul 1990, now patented, Pat. No. US 5198339
DT Utility
FS Granted
EXNAM Primary Examiner: Scheiner, Toni R.
LREP Arnold, White & Durkee
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of detecting gram-negative bacterial endotoxin using antibody capture combined with amoebocyte lysate chromogenic detection. The method is highly sensitive and rapid and may be used for detection of specific endotoxin. In a particular application, picogram levels of Haemophilus influenzae type b endotoxin are detected in plasma taken from previously infected mammals. In another particular application, the method is applied to the detection and diagnosis of disease, through the detection of endotoxin from disease-causing organisms. A specific example is the diagnosis of chancroid through the detection of endotoxin from H. ducreyi.

L8 ANSWER 23 OF 24 USPATFULL on STN
AN 93:24815 USPATFULL
TI Method for detection of gram-negative bacterial lipopolysaccharides in biological fluids
IN Hansen, Eric J., Plano, TX, United States
Munford, Robert S., Dallas, TX, United States
Mertsola, Jussi, Kaarina, Finland
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5198339 19930330
AI US 1990-553072 19900713 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Scheiner, Toni R.
LREP Arnold, White & Durkee
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of detecting gram-negative bacterial endotoxin using antibody capture combined with amoebocyte lysate chromogenic detection. The method is highly sensitive and rapid and may be used for detection of specific endotoxin. In a particular application, picogram levels of Haemophilus influenzae are detected in plasma taken from previously infected mammals.

L8 ANSWER 24 OF 24 USPATFULL on STN
AN 92:25476 USPATFULL
TI Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
IN Burns, Drusilla L., Washington, DC, United States
Brennan, Michael J., Kensington, MD, United States
Gould-Kostka, Jeanine L., Rockville, MD, United States
Manclark, Charles R., Rockville, MD, United States
PA United States of America, Washington, DC, United States (U.S. government)
PI US 5101014 19920331
AI US 1989-308864 19890210 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Moskowitz, Margaret; Assistant Examiner: Furman, Keith C.
LREP Cushman, Darby & Cushman
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises a method for the purification of the 69 kDa outer membrane protein of Bordetella B. pertussis and the protein purified therewith. A preferred embodiment comprises the purification of the 69 kDa protein from Bordetella B. pertussis strain Bp 353. The present process is advantageous in that it does not require or involve the use of biologics (such as monoclonal antibodies) and therefore simplifies the purification procedure and makes the resulting purified protein particularly advantageous for inclusion in acellular vaccines.

=> s l4 and (zwiterionic) and betaine
L9 0 L4 AND (ZWITERIONIC) AND BETAINE

=> s l4 and zwiterionic
L10 0 L4 AND ZWITERIONIC

=> s l4 and zwitterionic
L11 8 L4 AND ZWITTERIONIC

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 7 DUP REM L11 (1 DUPLICATE REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L12 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 2002:180973 CAPLUS
DN 136:231229
TI Preparation and immunogenicity of ***lipooligosaccharide*** -depleted outer membrane proteins of Gram-negative cocci
IN Zlotnick, Gary W.
PA American Cyanamid Company, USA
SO U.S., 13 pp., Cont.-in-part of U.S. Ser. No. 61,581, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 6355253	B1	20020312	US 1995-469842	19950606
	AT 190502	E	20000415	AT 1994-106827	19940502
	ES 2145072	T3	20000701	ES 1994-106827	19940502
	PT 624376	T	20000731	PT 1994-106827	19940502
	CA 2123355	AA	19941114	CA 1994-2123355	19940511
	JP 08019396	A2	19960123	JP 1994-122032	19940512
	GR 3033469	T3	20000929	GR 2000-401165	20000522
	US 2002136741	A1	20020926	US 2002-91233	20020305
PRAI	US 1993-61581	B2	19930513		
	US 1995-469842	A3	19950606		

AB The author discloses a method for removing ***lipooligosaccharide*** (LOS) from outer membranes of Gram-neg. cocci, such as Neisseria meningitidis. The method is comprised of sequential extn. of bacterial membranes with (1) a polyoxyethylene detergent (e.g., Triton X-100) followed by (2) a ***zwitterionic*** betaine detergent. LOS-depleted outer membranes and LOS-depleted sol. outer membrane proteins of N. meningitidis are able to elicit bactericidal antibodies against homologous strains of the bacteria.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 7 USPATFULL on STN
AN 2002:280552 USPATFULL
TI Kyberdrug as autovaccines with immune-regulating effects
IN Zimmermann, Kurt, Herborn-Seelbach, GERMANY, FEDERAL REPUBLIC OF
Paradies, H. Henrich, Iserlohn, GERMANY, FEDERAL REPUBLIC OF
Rusch, Volker, Herborn, GERMANY, FEDERAL REPUBLIC OF
PI US 2002155997 A1 20021024
AI US 2001-971557 A1 20011005 (9)
PRAI US 2000-238656P 20001006 (60)
US 2001-263494P 20010123 (60)
DT Utility
FS APPLICATION
LREP SCULLY, SCOTT, MUPRHY & PRESSER, 400 Garden City Plaza, Garden City, NY, 11530
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3156
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a "Kyberdrug" and to a pharmaceutical composition containing an effective amount of the Kyberdrug and a pharmaceutical carrier therefor, and its medicinal use as an immune modulating drug exhibiting autovaccine-like activities.

L12 ANSWER 3 OF 7 USPATFULL on STN
AN 2002:250803 USPATFULL
TI Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
IN Zlotnick, Gary W., Penfield, NY, UNITED STATES
PA American Cyanamid Company, Madison, NY, UNITED STATES (U.S. corporation)
PI US 2002136741 A1 20020926
AI US 2002-91233 A1 20020305 (10)
RLI Division of Ser. No. US 1995-469842, filed on 6 Jun 1995, GRANTED, Pat. No. US 6355253 Continuation-in-part of Ser. No. US 1993-61581, filed on 13 May 1993, ABANDONED
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein is a method for removing toxic ***lipooligosaccharide*** (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis.LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of

bacteria. Vaccines and other uses of the preparations are further described.

L12 ANSWER 4 OF 7 USPATFULL on STN
AN 2000:27773 USPATFULL
TI Peptide expression and delivery system
IN Murphy, Timothy F., East Amherst, NY, United States
Yi, Kyungcheol, Lilburn, GA, United States
PA Research Foundation of State University of New York, Amherst, NY, United States (U.S. corporation)
PI US 6033877 20000307
AI US 1996-740644 19961031 (8)
PRAI US 1996-6168P 19961102 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David; Assistant Examiner: Larson, Thomas G.
LREP Hodgson, Russ, Andrews, Woods & Goodyear LLP
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods and compositions for producing a fusion protein comprised of Haemophilus influenzae P2 amino acid sequences, wherein in place of loop 5, or a portion thereof, is displayed a heterologous or homologous peptide sequence having biological activity. The fusion protein may be expressed on the surface of the host cell, such as in H. influenzae, which has been transformed with a fusion sequence that is operatively linked to at least one regulatory control element for expression of the fusion protein. Alternatively, the fusion protein can be purified from the host cell in the expression system, if the fusion protein remains associated with the host cell; or from the media of the expression system, if the fusion protein is a secreted form.

L12 ANSWER 5 OF 7 USPATFULL on STN
AN 1999:166603 USPATFULL
TI Outer membrane protein B1 of Moraxella catarrhalis
IN Campagnari, Anthony A., Hamburg, NY, United States
PA The Research Foundation of the State University of New York, Amherst, NY, United States (U.S. corporation)
PI US 6004562 19991221
AI US 1996-698652 19960816 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Ryan, V.
LREP Hodgson, Russ, Andrews, Woods & Goodyear, LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An isolated and purified outer membrane protein B1, and peptides formed therefrom, of Moraxella catarrhalis are described. A method for the isolation and purification of outer membrane protein B1 from a bacterial strain that produces B1 protein, e.g. Moraxella catarrhalis, comprises growing the bacteria in culture in iron-depleted medium to enhance the expression of the B1 protein, harvesting the bacteria from the culture, extracting from the harvested bacteria a preparation substantially comprising an outer membrane protein preparation, contacting the outer membrane preparation with an affinity matrix containing immobilized transferrin wherein B1 protein binds to the transferrin, and eluting the bound B1 protein from the transferrin. Disclosed are the uses of the B1 protein as an immunogen for vaccine formulations, and as antigens in diagnostic immunoassays.

L12 ANSWER 6 OF 7 USPATFULL on STN
AN 1998:9349 USPATFULL
TI Vaccine for branhamella catarrhalis
IN Murphy, Timothy F., East Amherst, NY, United States
PA Research Foundation of State University of New York, Amherst, NY, United

States (U.S. corporation)
PI US 5712118 19980127
AI US 1994-306871 19940920 (8)
RLI Continuation-in-part of Ser. No. US 1993-129719, filed on 29 Sep 1993, now patented, Pat. No. US 5556755, issued on 17 Sep 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Minnifield, N. M.
LREP Hodgson, Russ, Andrews, Woods & Goodyear
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising outer membrane protein "CD", and peptides and oligopeptides thereof, of Branhamella catarrhalis are described. Additionally, nucleotide sequences encoding the protein, peptide or oligopeptide are disclosed, as well as recombinant vectors containing these sequences. Protein, peptide or oligopeptide can be produced from host cell systems containing these recombinant vectors. Peptides and oligopeptides can also be chemically synthesized. Disclosed are the uses of the protein, peptides and oligopeptides as antigens for vaccine formulations, and as antigens in diagnostic immunoassays. The nucleotide sequences are useful for constructing vectors for use as vaccines for insertion into attenuated bacteria in constructing a recombinant bacterial vaccine, and for inserting into a viral vector in constructing a recombinant viral vaccine. Also described is the use of nucleotide sequences related to the gene encoding CD as primers and/or probes in molecular diagnostic assays for the detection of B. catarrhalis.

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:260096 CAPLUS
DN 122:38807
TI ***lipooligosaccharide*** -depleted antigenic outer membrane proteins of gram-negative cocci
IN Zlotnick, Gary W.
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 624376	A1	19941117	EP 1994-106827	19940502
	EP 624376	B1	20000315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 190502	E	20000415	AT 1994-106827	19940502
	ES 2145072	T3	20000701	ES 1994-106827	19940502
	PT 624376	T	20000731	PT 1994-106827	19940502
	CA 2123355	AA	19941114	CA 1994-2123355	19940511
	JP 08019396	A2	19960123	JP 1994-122032	19940512
	GR 3033469	T3	20000929	GR 2000-401165	20000522
PRAI	US 1993-61581	A	19930513		

AB A method for removing toxic ***lipooligosaccharide*** (LOS) from outer membranes of gram-neg. cocci, such as Neisseria meningitidis, is presented. Total membranes of the coccus are extd. with PEG to produce outer membranes depleted of inner membranes; the outer membranes are then extd. with a ***zwitterionic*** betaine detergent to remove LOS. The LOS-depleted outer membranes are able to elicit bactericidal antibodies against homologous strains of bacteria, and are useful in vaccines.

=> s l4 and betaine
L13 8 L4 AND BETAINE

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14 7 DUP REM L13 (1 DUPLICATE REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L14 ANSWER 1 OF 7 USPATFULL on STN
AN 2004:12957 USPATFULL
TI Methods for producing libraries of expressible gene sequences
IN Fernandez, Joseph M., Carlsbad, CA, UNITED STATES
Heyman, John A., Rixensart, BELGIUM
Hoeffler, James P., Anchorage, AK, UNITED STATES
Marks-Hull, Heather L., Oceanside, CA, UNITED STATES
Sindici, Michelle L., San Diego, CA, UNITED STATES
PA INVITROGEN CORPORATION (U.S. corporation)
PI US 2004009477 A1 20040115
AI US 2001-990091 A1 20011121 (9)
RLI Continuation of Ser. No. US 2001-843281, filed on 25 Apr 2001, ABANDONED
Continuation of Ser. No. US 647651, ABANDONED A 371 of International
Ser. No. WO 1999-US7270, filed on 2 Apr 1999, PENDING
Continuation-in-part of Ser. No. US 1998-54936, filed on 3 Apr 1998,
ABANDONED
PRAI US 1999-7270 19990402
DT Utility
FS APPLICATION
LREP LISA A. HAILE, Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365
Executive Drive, San Diego, CA, 92121-2133
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4754
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises a method for producing libraries of
expressible gene sequences. The method of the invention allows for the
simultaneous manipulation of multiple gene sequences and thus allows
libraries to be created in an efficient and high throughput manner. The
expression vectors containing verified gene sequences can be used to
transfect cells for the production of recombinant proteins. The
invention further comprises libraries of expressible gene sequences
produced using the method of the invention and expression vectors used
in the construction of said libraries.

L14 ANSWER 2 OF 7 USPATFULL on STN
AN 2003:194491 USPATFULL
TI Libraries of expressible gene sequences
IN Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PA INVITROGEN CORPORATION (U.S. corporation)
PI US 2003134302 A1 20030717
AI US 2002-210985 A1 20020801 (10)
RLI Continuation of Ser. No. US 2001-3021, filed on 14 Nov 2001, PENDING
Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, ABANDONED
PRAI US 1998-96981P 19980818 (60)
US 1998-80626P 19980403 (60)
DT Utility
FS APPLICATION
LREP Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite
1100, 4365 Executive Drive, San Diego, CA, 92121-2133
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 9810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention described herein comprises libraries of expressible gene
sequences. Such gene sequences are contained on plasmid vectors designed
to endow the expressed proteins with a number of useful features such as
affinity purification tags, epitope tags, and the like. The expression
vectors containing such gene sequences can be used to transfect cells
for the production of recombinant proteins. A further aspect of the
invention comprises methods of identifying binding partners for the
products of such expressible gene sequences.

L14 ANSWER 3 OF 7 USPATFULL on STN
AN 2003:106252 USPATFULL
TI Libraries of expressible gene sequences
IN Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PA INVITROGEN CORPORATION (U.S. corporation)
PI US 2003073163 A1 20030417
AI US 2001-3021 A1 20011114 (10)
RLI Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, PENDING
PRAI US 1998-96981P 19980818 (60)
US 1998-80626P 19980403 (60)
DT Utility
FS APPLICATION
LREP Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 9813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

L14 ANSWER 4 OF 7 USPATFULL on STN
AN 2003:240330 USPATFULL
TI Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
IN Doucette-Stamm, Lynn A., 14 Flanagan Dr., Framingham, MA, United States 01701
Bush, David, 205 Holland St., Somerville, MA, United States 02144
PI US 6617156 B1 20030909
AI US 1998-134000 19980813 (9)
PRAI US 1997-55778P 19970815 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mosher, Mary E.
LREP Genome Therapeutics Corporation
CLMN Number of Claims: 19
ECL Exemplary Claim: 1,5,14
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 13738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Enterococcus faecalis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 2002:180973 CAPLUS
DN 136:231229
TI Preparation and immunogenicity of ***lipooligosaccharide*** -depleted outer membrane proteins of Gram-negative cocci
IN Zlotnick, Gary W.
PA American Cyanamid Company, USA
SO U.S., 13 pp., Cont.-in-part of U.S. Ser. No. 61,581, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6355253	B1	20020312	US 1995-469842	19950606

	AT 190502	E	20000415	AT 1994-106827	19940502
	ES 2145072	T3	20000701	ES 1994-106827	19940502
	PT 624376	T	20000731	PT 1994-106827	19940502
	CA 2123355	AA	19941114	CA 1994-2123355	19940511
	JP 08019396	A2	19960123	JP 1994-122032	19940512
	GR 3033469	T3	20000929	GR 2000-401165	20000522
	US 2002136741	A1	20020926	US 2002-91233	20020305
PRAI	US 1993-61581	B2	19930513		
	US 1995-469842	A3	19950606		

AB The author discloses a method for removing ***lipooligosaccharide*** (LOS) from outer membranes of Gram-neg. cocci, such as Neisseria meningitidis. The method is comprised of sequential extn. of bacterial membranes with (1) a polyoxyethylene detergent (e.g., Triton X-100) followed by (2) a zwitterionic ***betaine*** detergent. LOS-depleted outer membranes and LOS-depleted sol. outer membrane proteins of N. meningitidis are able to elicit bactericidal antibodies against homologous strains of the bacteria.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 7 USPATFULL on STN
AN 2002:250803 USPATFULL
TI Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
IN Zlotnick, Gary W., Penfield, NY, UNITED STATES
PA American Cyanamid Company, Madison, NY, UNITED STATES (U.S. corporation)
PI US 2002136741 A1 20020926
AI US 2002-91233 A1 20020305 (10)
RLI Division of Ser. No. US 1995-469842, filed on 6 Jun 1995, GRANTED, Pat. No. US 6355253 Continuation-in-part of Ser. No. US 1993-61581, filed on 13 May 1993, ABANDONED
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein is a method for removing toxic ***lipooligosaccharide*** (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis.LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.

L14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:260096 CAPLUS
DN 122:38807
TI ***lipooligosaccharide*** -depleted antigenic outer membrane proteins of gram-negative cocci
IN Zlotnick, Gary W.
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 624376	A1	19941117	EP 1994-106827	19940502
	EP 624376	B1	20000315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 190502	E	20000415	AT 1994-106827	19940502
	ES 2145072	T3	20000701	ES 1994-106827	19940502
	PT 624376	T	20000731	PT 1994-106827	19940502
	CA 2123355	AA	19941114	CA 1994-2123355	19940511
	JP 08019396	A2	19960123	JP 1994-122032	19940512
	GR 3033469	T3	20000929	GR 2000-401165	20000522

PRAI US 1993-61581 A 19930513

AB A method for removing toxic ***lipooligosaccharide*** (LOS) from outer membranes of gram-neg. cocci, such as Neisseria meningitidis, is presented. Total membranes of the coccus are extd. with PEG to produce outer membranes depleted of inner membranes; the outer membranes are then extd. with a zwitterionic ***betaine*** detergent to remove LOS. The LOS-depleted outer membranes are able to elicit bactericidal antibodies against homologous strains of bacteria, and are useful in vaccines.